Potsdam, Germany, June 3, 2016 / B3C newswire / -- The medical technology company Emperra was selected to participate in the German Accelerator Life Sciences (GALS) program. The initiative of the Federal Ministry for Economic Affairs and Energy supports young German medical and healthcare companies in expanding into the lucrative US market.

Christoph Lengauer, the CEO of GALS, stated "We are excited to work with Emperra. Integrated solutions such as ESYSTA have the potential to change the way we provide diabetes care. Emperra's approach can improve the lives of millions of patients." GALS and Emperra will prepare in the next months the market entry in the US.  Together with GALS, Emperra has set ambitious goals for the future. The CEO of Emperra, Dr. Christian Krey, emphasized that “for Emperra, a successful launch of the ESYSTA system in the U.S. is an important milestone on the way to become a globally successful company with an unique Diabetes Management Program. We are really looking forward to the opportunity to take this important step with the support of GALS.”

It is of particular advantage that the GALS has recently opened an office in Berlin. The Program Director for Germany, Jared Sebhatu, and his team will be located at Mindspace, a co-working hub in Berlin’s Friedrichstrasse. GALS covers the costs for the mentor program and infrastructure for office space in Boston, MA. Moreover, the initiative grants the German young entrepreneurs access to an extensive network of experts.

Emperras ESYSTA® digital health solution provides self-empowerment and decision support for patients with insulin dependent Diabetes mellitus and connects them remotely with physicians, relatives and caregivers. For the first time, diabetes data management, analytics and connected devices - like the smart Emperra insulin pen and blood glucose meter - have been combined to improve the management of diabetes with real time analytics. With the ubiquity of cloud based electronic e-health management among all stakeholders via computers, tablets and smartphones the ESYSTA system enables improved treatment and patient guidance. Medical and economic benefits were proven in a study in cooperation with a health-insurer as significant reduction of HbA1c over 12 months as well as a reduction in insulin consumption without a higher rate of hypoglycemic events were shown. The system meets all requirements pertaining to medical products as defined by CE (DIN EN ISO 13485) and to reliable data management. The data is stored in encrypted form on highly secure servers which satisfy the strictest IT security standard in accordance with ISO / IEC 27001:2013.

“The unique environment with MIT, Harvard and the well-known Joslin Diabetes Center will help us to perform clinical studies in Boston”, says Krey, “and also to accelerate our US launch.”

The fact that Emperra was selected to GALS fits very well into the increasing international visibility and reputation of Emperra. Last year the International Journal of mHealth awarded the 2015 Global Digital Health Award and Emperra was elected into the top 100 of the world's eHealth drivers.

About Emperra GmbH E-Health Technologies Emperra GmbH E-Health Technologies is a research and development-focused medical technology start-up company from Potsdam that offers innovative concepts and solutions in the fields of e-health technology and tele-diabetology. Emperra combines innovative software with ground-breaking hardware and integrates these into a medical and scientific concept aimed at providing doctors, patients, caregivers and relatives with telemedicine-based product systems.

About the German Accelerator Life Sciences The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy, with the goal of helping German startups and young companies to be successful in the global marketplace. GALS offers support in multiple areas, from free office space in the world’s leading life science innovation hub Boston, to mentoring and advising from industry experts and experienced leaders in the space. GALS opened its doors in October 2015 and has its headquarters in Cambridge, Massachusetts.

Contacts

Emperra Dr. Christian Krey CEO EMPERRA GmbH E-Health Technologies Friedrich-Ebert-Straße 33 14469 Potsdam Germany +49 331 - 979 34 80 0 c.krey@emperra.com https://www.emperra.com

GALS Jared Sebhatu Program Director, Germany German Accelerator Life Sciences c/o Mindspace Friedrichstrasse 68 10117 Berlin Germany (+49) 175 413 0094 jared.sebhatu@germanaccelerator.com http://www.germanaccelerator.com/life-sciences